353 related articles for article (PubMed ID: 26411904)
1. cGMP-Manufactured Human Induced Pluripotent Stem Cells Are Available for Pre-clinical and Clinical Applications.
Baghbaderani BA; Tian X; Neo BH; Burkall A; Dimezzo T; Sierra G; Zeng X; Warren K; Kovarcik DP; Fellner T; Rao MS
Stem Cell Reports; 2015 Oct; 5(4):647-59. PubMed ID: 26411904
[TBL] [Abstract][Full Text] [Related]
2. Human-Induced Pluripotent Stem Cell Culture Methods Under cGMP Conditions.
Rivera T; Zhao Y; Ni Y; Wang J
Curr Protoc Stem Cell Biol; 2020 Sep; 54(1):e117. PubMed ID: 32649060
[TBL] [Abstract][Full Text] [Related]
3. Generation of Xeno-Free, cGMP-Compliant Patient-Specific iPSCs from Skin Biopsy.
Wiley LA; Anfinson KR; Cranston CM; Kaalberg EE; Collins MM; Mullins RF; Stone EM; Tucker BA
Curr Protoc Stem Cell Biol; 2017 Aug; 42():4A.12.1-4A.12.14. PubMed ID: 28806854
[TBL] [Abstract][Full Text] [Related]
4. cGMP-Compliant Expansion of Human iPSC Cultures as Adherent Monolayers.
Parr AM; Walsh PJ; Truong V; Dutton JR
Methods Mol Biol; 2016; 1357():221-9. PubMed ID: 25863788
[TBL] [Abstract][Full Text] [Related]
5. Long-Term Stability and Differentiation Potential of Cryopreserved cGMP-Compliant Human Induced Pluripotent Stem Cells.
Shafa M; Walsh T; Panchalingam KM; Richardson T; Menendez L; Tian X; Suresh Babu S; Dadgar S; Beller J; Yang F; Baghbaderani BA
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877913
[TBL] [Abstract][Full Text] [Related]
6. Human-Induced Pluripotent Stem Cells Manufactured Using a Current Good Manufacturing Practice-Compliant Process Differentiate Into Clinically Relevant Cells From Three Germ Layers.
Shafa M; Yang F; Fellner T; Rao MS; Baghbaderani BA
Front Med (Lausanne); 2018; 5():69. PubMed ID: 29600249
[TBL] [Abstract][Full Text] [Related]
7. Detailed Characterization of Human Induced Pluripotent Stem Cells Manufactured for Therapeutic Applications.
Baghbaderani BA; Syama A; Sivapatham R; Pei Y; Mukherjee O; Fellner T; Zeng X; Rao MS
Stem Cell Rev Rep; 2016 Aug; 12(4):394-420. PubMed ID: 27283945
[TBL] [Abstract][Full Text] [Related]
8. Illustrating the potency of current Good Manufacturing Practice-compliant induced pluripotent stem cell lines as a source of multiple cell lineages using standardized protocols.
Rao MS; Pei Y; Garcia TY; Chew S; Kasai T; Hisai T; Taniguchi H; Takebe T; Lamba DA; Zeng X
Cytotherapy; 2018 Jun; 20(6):861-872. PubMed ID: 29793831
[TBL] [Abstract][Full Text] [Related]
9. Induced Pluripotent Stem Cells: Generation, Characterization, and Differentiation--Methods and Protocols.
Graversen VK; Chavala SH
Methods Mol Biol; 2016; 1357():395-401. PubMed ID: 25403469
[TBL] [Abstract][Full Text] [Related]
10. Can cord blood banks transform into induced pluripotent stem cell banks?
Zhou H; Rao MS
Cytotherapy; 2015 Jun; 17(6):756-764. PubMed ID: 25770678
[TBL] [Abstract][Full Text] [Related]
11. Derivation of Neural Stem Cells from Mouse Induced Pluripotent Stem Cells.
Karanfil I; Bagci-Onder T
Methods Mol Biol; 2016; 1357():329-38. PubMed ID: 25863785
[TBL] [Abstract][Full Text] [Related]
12. Induced pluripotent stem cell technology: A window for studying the pathogenesis of acquired aplastic anemia and possible applications.
Elbadry MI; Espinoza JL; Nakao S
Exp Hematol; 2017 May; 49():9-18. PubMed ID: 28062362
[TBL] [Abstract][Full Text] [Related]
13. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease.
Son MY; Lee MO; Jeon H; Seol B; Kim JH; Chang JS; Cho YS
Exp Mol Med; 2016 May; 48(5):e232. PubMed ID: 27174201
[TBL] [Abstract][Full Text] [Related]
14. Scalable production of transplantable dopaminergic neurons from hESCs and iPSCs in xeno-free defined conditions.
Swistowski A; Zeng X
Curr Protoc Stem Cell Biol; 2012 Aug; Chapter 2():Unit2D.12. PubMed ID: 22872425
[TBL] [Abstract][Full Text] [Related]
15. Sendai Virus-Based Reprogramming of Mesenchymal Stromal/Stem Cells from Umbilical Cord Wharton's Jelly into Induced Pluripotent Stem Cells.
Miere C; Devito L; Ilic D
Methods Mol Biol; 2016; 1357():33-44. PubMed ID: 26246353
[TBL] [Abstract][Full Text] [Related]
16. GMP-compatible manufacturing of three iPS cell lines from human peripheral blood.
Haase A; Glienke W; Engels L; Göhring G; Esser R; Arseniev L; Martin U
Stem Cell Res; 2019 Mar; 35():101394. PubMed ID: 30772682
[TBL] [Abstract][Full Text] [Related]
17. Derivation of GMP-compliant integration-free hiPSCs using modified mRNAs.
Durruthy JD; Sebastiano V
Methods Mol Biol; 2015; 1283():31-42. PubMed ID: 25304205
[TBL] [Abstract][Full Text] [Related]
18. Enhancing Induced Pluripotent Stem Cell Generation by MicroRNA.
Dang J; Rana TM
Methods Mol Biol; 2016; 1357():71-84. PubMed ID: 25687299
[TBL] [Abstract][Full Text] [Related]
19. A reproducible and versatile system for the dynamic expansion of human pluripotent stem cells in suspension.
Elanzew A; Sommer A; Pusch-Klein A; Brüstle O; Haupt S
Biotechnol J; 2015 Oct; 10(10):1589-99. PubMed ID: 26110829
[TBL] [Abstract][Full Text] [Related]
20. Good Manufacturing Practice-compliant human induced pluripotent stem cells: from bench to putative clinical products.
Novoa JJ; Westra IM; Steeneveld E; Fonseca Neves N; Arendzen CH; Rajaei B; Grundeken E; Yildiz M; van der Valk W; Salvador A; Carlotti F; Dijkers PF; Locher H; van den Berg CW; Raymond KI; Kirkeby A; Mummery CL; Rabelink TJ; Freund C; Meij P; Wieles B
Cytotherapy; 2024 Jun; 26(6):556-566. PubMed ID: 38483359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
